TLDRs
- SELLAS rises as AML trial nears final survival event trigger
- Investors await imminent Phase 3 REGAL data analysis milestone
- Stock gains on hopes of late-stage cancer readout completion
- Biotech watches SELLAS binary outcome in AML study closely
SELLAS Life Sciences Group shares extended gains as investors positioned around a critical inflection point in its flagship late-stage cancer study.
The company’s Phase 3 REGAL trial in acute myeloid leukemia (AML) is now approaching the final “event” threshold required to unlock overall survival data, one of the most closely watched readouts in the biotech sector.
The stock closed at $7.59, up roughly 4.1%, reflecting renewed optimism that the trial is nearing completion. The move came even as broader biotech indexes showed mixed performance, underscoring the stock-specific nature of the rally.
SELLAS Life Sciences Group, Inc., SLS
Investors Focus on Data Timing
Market attention is centered on timing rather than new efficacy results. SELLAS previously disclosed that 78 of the 80 required events in the study had already occurred, meaning the trial is effectively at the finish line.
Chief Executive Officer Angelos Stergiou recently reiterated at an oncology forum that the company expects data “very soon,” while analysts noted the company is now only a few events away from triggering final analysis. Once the 80th event occurs, SELLAS expects a short period of data cleaning before results can be interpreted and shared.
Because the trial is event-driven, its conclusion depends entirely on patient outcomes rather than a fixed calendar date, adding uncertainty but also compressing the timeline for potential catalysts.
Biotech Trade Remains Binary
The REGAL study evaluates galinpepimut-S (GPS) in patients with AML in second complete remission, comparing it against best available therapy. The primary endpoint is overall survival, making this readout potentially decisive for the drug’s future development path.
The setup remains highly binary. A positive result could support regulatory filings and significantly expand the drug’s commercial prospects. However, a failure to demonstrate meaningful survival benefit would likely reset investor expectations and pressure the stock given its current valuation sensitivity.
SELLAS has emphasized that it remains blinded to trial outcomes, meaning neither the company nor investors have visibility into which treatment arms are performing better.
Pipeline and Cash Position in Focus
Beyond REGAL, investors are also watching SELLAS’ broader pipeline. The company is advancing SLS009 (tambiciclib), a CDK9 inhibitor designed to target cancer cell survival pathways. Early-stage and preclinical data have suggested potential activity in AML, and top-line Phase 2 results are expected later this year.
Management has positioned SLS009 as a complementary asset that could extend SELLAS’ oncology footprint if clinical outcomes are positive.
Financially, the company reported $107.1 million in cash and cash equivalents as of March 31, boosted by warrant exercises earlier in the year. While this provides short-term runway, SELLAS continues to operate without product revenue and has ongoing losses, leaving potential reliance on capital markets or its at-the-market equity program for future funding needs.
Competitive AML Landscape Intensifies
The AML treatment landscape remains competitive, with established regimens such as venetoclax combinations and Bristol Myers Squibb’s ONUREG already in use across different patient populations. This raises the stakes for SELLAS, as any approved therapy must demonstrate clear differentiation in survival outcomes or clinical positioning.
As investors await the final event trigger, SELLAS remains firmly in the spotlight as one of the more closely watched small-cap biotech catalysts in the market.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
